In This Section:

◄

Case Studies

Clinical publications

Editorials

Guidelines

Radcliffe Content

Review Articles

►

Cardiomyopathy

Welcome to our featured section on cardiomyopathy

Click here to take the CME-accredited courses.

This educational hub pulls together the latest clinical data, guidelines, congress updates as well as original video content and expert interviews on the management of cardiomyopathies. Some of the content on this hub will be CME-accredited and credits will be available when viewed on Radcliffe Medical Education – our dedicated CME portal. Instructions on how to do so are provided with individual videos.

See more ▼

Close X

Recent Videos

Video

AHA 24: The REMS Program for Mavacamten

Milind Y Desai,

Watch time: 7m 19s

Video

AHA 24: The VALOR-HCM Trial

Milind Y Desai,

Watch time: 10m 31s

Video Series

e-SPACE Heart Failure 2024

Maria Rosa Costanzo, JoAnn Lindenfeld, Nicolas Girerd, et al

Broadcast

e-SPACE HF 2024 – Day Two

Clara Saldarriaga, Gianluigi Savarese, Javed Butler, et al

Broadcast

e-SPACE HF 2024 – Day One

Clara Saldarriaga, Gianluigi Savarese, Javed Butler, et al

Video Series

Advancing Patient Care in Hypertrophic Cardiomyopathy

Ahmad Masri, Caroline Coats,

Case Studies

Hypertrophic cardiomyopathy as an unexpected mimic of inducible laryngeal obstruction: the case for cardiopulmonary exercise testing in otolaryngology

Wertheim BM, Kapur S, Lakdawala NK, Carroll TL. J Voice 2023;37:97–100.

Effective treatment of hypertrophic cardiomyopathy with left ventricular outflow tract obstruction using a covered stent

Pekas D, Chawda A, Desai N. BMJ Case Rep 2022;15:e250929.

Hypertrophic cardiomyopathy and left ventricular non-compaction cardiomyopathy: two in one

Gabra B, Anavekar NS, Haaf P. Eur Heart J 2023;44:327.

Concerns with patient reported outcome measurement and value claims for therapy response: the case of mavacamten and symptomatic hypertrophic cardiomyopathy (SHCM)

Langley PC. Innov Pharm 2022;13:10.24926/iip.v13i2.4861.

Hypertrophic cardiomyopathy with extreme outflow tract obstruction

Geske JB, Stephens EH, Dearani JA. Eur Heart J 2022;43:4518.

Multimodality imaging of LEOPARD syndrome: myocardial hypertrophy with diffuse coronary artery dilation

Yang D, Wang Y, Lu M. JACC Case Rep 2022;4:1042–8.

Clinical publications

Entropy of left ventricular late gadolinium enhancement and its prognostic value in hypertrophic cardiomyopathy a new CMR assessment method

Zhao X, Jin F, Wang J, et al. Int J Cardiol 2023;373:134–41.

Efficacy of SGLT2 inhibitors in patients with diabetes and nonobstructive hypertrophic cardiomyopathy

Subramanian M, Sravani V, Krishna SP, et al. Am J Cardiol 2023;188:80–6.

Implications of structural right ventricular involvement in patients with hypertrophic cardiomyopathy

Zhang Y, Zhu Y, Zhang M, et al. Eur Heart J Qual Care Clin Outcomes 2023;9:34–41.

Impact of hospital volume on outcomes of septal myectomy for hypertrophic cardiomyopathy

Holst KA, Schaff HV, Smedira NG, et al. Ann Thorac Surg 2022;114:2131–8.

Detecting regional fibrosis in hypertrophic cardiomyopathy: the utility of myocardial strain based on cardiac magnetic resonance

She J, Zhao S, Chen Y, et al. Acad Radiol 2023;30:230–8.

Clinical features of heart failure in patients with hypertrophic cardiomyopathy in a regional Japanese cohort　― results from the Kochi RYOMA study ―

Miyamoto Y, Kubo T, Ochi Y, et al. Circ J 2022;86:1934–40.

Impact of race and ethnicity on use and outcomes of septal reduction therapies for obstructive hypertrophic cardiomyopathy

Patlolla SH, Schaff HV, Nishimura RA, et al. J Am Heart Assoc 2023;12:e026661.

Automated quantification of abnormal QRS peaks from high‐resolution ECGs predicts late ventricular arrhythmias in hypertrophic cardiomyopathy: a 5‐year prospective multicenter study

Suszko AM, Chakraborty P, Viswanathan K, et al. J Am Heart Assoc 2022;11:e026025.

Identification of transthyretin cardiac amyloidosis among patients previously diagnosed with hypertrophic cardiomyopathy

Rowin EJ, Ruberg FL, Das G, et al. Circ Cardiovasc Imaging 2022;15:e014938.

Is anterior mitral valve leaflet length important in outcome of septal myectomy for obstructive hypertrophic cardiomyopathy?

Lentz Carvalho J, Schaff HV, Nishimura RA, et al. J Thorac Cardiovasc Surg 2023;165:79–87.e1.

Using electronic health record data to improve understanding of the risk of mental disorders in patients diagnosed with hypertrophic cardiomyopathy

Jin K. Eur J Prev Cardiol 2023;30:82–4.

Risk of incident mental disorders in hypertrophic cardiomyopathy: a nationwide propensity-matched study

Park JB, Yun JY, Kim B, et al. Eur J Prev Cardiol 2023;30:85–94.

Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy

Wheeler MT, Jacoby D, Elliott PM, et al. Eur J Heart Fail 2022; epub ahead of press.

Survival after septal reduction in patients >65 years old with obstructive hypertrophic cardiomyopathy

Mentias A, Smedira NG, Krishnaswamy A, et al. J Am Coll Cardiol 2023;81:105–15.

Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy

Maron MS, Masri A, Choudhury L, et al. J Am Coll Cardiol 2023;81:34–45.

Myocardial activity at (18)F-FAPI PET/CT and risk for sudden cardiac death in hypertrophic cardiomyopathy

Wang L, Wang Y, Wang J, et al. Radiology 2022; epub ahead of press.

Longitudinal cost of septal myectomy versus alcohol septal ablation for hypertrophic cardiomyopathy

Sun D, Schaff HV, Van Houten HK, et al. Mayo Clin Proc 2022;97:1656–63.

Evidence of advanced pulmonary vascular remodeling in obstructive hypertrophic cardiomyopathy with pulmonary hypertension

Maron BA, Kleiner DE, Arons E, et al. Chest 2022; epub ahead of press.

Toward ECG-based analysis of hypertrophic cardiomyopathy: a novel ECG segmentation method for handling abnormalities

Nezamabadi K, Mayfield J, Li P, et al. J Am Med Inform Assoc 2022;29:1879–89.

Magnetique: an interactive web application to explore transcriptome signatures of heart failure

Britto-Borges T, Ludt A, Boileau E, et al. J Transl Med 2022;20:513.

Posterior wall thickness associates with survival following septal myectomy for obstructive hypertrophic cardiomyopathy

Sun D, Schaff HV, Nishimura RA, et al. JACC Heart Fail 2022;10:831–7.

Validation of the Kansas City Cardiomyopathy Questionnaire in symptomatic obstructive hypertrophic cardiomyopathy

Nassif M, Fine JT, Dolan C, et al. JACC Heart Fail 2022;10:531–9.

Outcomes of patients with hypertrophic obstructive cardiomyopathy and pacemaker implanted after alcohol septal ablation

Veselka J, Liebregts M, Cooper R, et al. JACC Cardiovasc Interv 2022;15:1910–7.

Clinical characteristics and prognostic importance of left ventricular apical aneurysms in hypertrophic cardiomyopathy

Lee DZJ, Montazeri M, Bataiosu R, et al. JACC Cardiovasc Imaging 2022;15:1696–711.

Coexistent diabetes is associated with the presence of adverse phenotypic features in patients with hypertrophic cardiomyopathy

Jex N, Chowdhary A, Thirunavukarasu S, et al. Diabetes Care 2022;45:1852–62.

Multinational federated learning approach to train ECG and echocardiogram models for hypertrophic cardiomyopathy detection

Goto S, Solanki D, John JE, et al. Circulation 2022;146:755–69.

Dose-blinded myosin inhibition in patients with obstructive HCM referred for septal reduction therapy: outcomes through 32-weeks

Desai MY, Owens AT, Geske JB, et al. Circulation 2022; epub ahead of press.

Single-nucleus profiling of human dilated and hypertrophic cardiomyopathy

Chaffin M, Papangeli I, Simonson B, et al. Nature 2022;608:174–80.

The prevalence and association of exercise test abnormalities with sudden cardiac death and transplant-free survival in childhood hypertrophic cardiomyopathy

Conway J, Min S, Villa C, et al. Circulation 2022; epub ahead of press.

Natural history of MYH7-related dilated cardiomyopathy

de Frutos F, Ochoa JP, Navarro-Peñalver M, et al. J Am Coll Cardiol 2022;80:1447–61.

Editorials

Syncope in hypertrophic cardiomyopathy: explaining the unexplained

Geske JB, Siontis KC, Gersh BJ. Int J Cardiol 2023;373:99–100.

High‐resolution ECG for predicting ventricular arrhythmia in hypertrophic cardiomyopathy: another tool in the toolbox

Gehi AK. J Am Heart Assoc 2022;11:e028095.

Composite endpoints in hypertrophic cardiomyopathy: practice, education, research

Ommen SR. JACC Heart Fail 2023;11:42–3.

Mavacamten in obstructive hypertrophic cardiomyopathy – are beta-blockers blocking part of its shine?

Dominguez F, Cabrera E. Eur J Heart Fail 2023; epub ahead of press.

Increased long-term survival after myectomy: is the pendulum swinging again in this 30-year debate?

Maron MS. J Am Coll Cardiol 2023;81:116–8.

Myosin inhibitors: the next generation

Nair A, Xie L, Silva Enciso JE. J Am Coll Cardiol 2023;81:46–8.

Commentary: invasive therapy for hypertrophic obstructive cardiomyopathy: is it time to reexamine the guidelines?

Mazine A, Tam DY, Fremes SE. J Thorac Cardiovasc Surg 2022;164:1511–3.

Commentary: septal reduction therapy: the sooner, the better?

Wei LM. J Thorac Cardiovasc Surg 2022;164:1513–4.

Evolving epidemiology of hypertrophic cardiomyopathy: shifting the focus from instant to lifetime risk awareness

Canepa M, Olivotto I. Circ Heart Fail 2022;15:e009873.

Refining endpoint measures in clinical trials for hypertrophic cardiomyopathy: the emerging role of patient-reported outcomes

Rowin EJ, Maron MS. JACC Heart Fail 2022;10:540–2.

Left ventricular posterior wall in obstructive hypertrophic cardiomyopathy: a neglected issue in clinical management?

de Gregorio C, Luongo A. JACC Heart Fail 2022;10:838–41.

New pacemaker implantation after alcohol septal ablation: how sharp is the double-edged sword?

Pineda AM, Wang A. JACC Cardiovasc Interv 2022;15:1918–20.

Understanding the prognostic significance of left ventricular apical aneurysms in hypertrophic cardiomyopathy

Elliott PM, Lorenzini M. JACC Cardiovasc Imaging 2022;15:1712–4.

Myosin-related dilated cardiomyopathy: another elephant emerges from darkness

Lanfear DE, Reza N. J Am Coll Cardiol 2022;80:1462–4.

Guidelines

Syncope in hypertrophic cardiomyopathy (part II): an expert consensus statement on the diagnosis and management

Brignole M, Cecchi F, Anastasakis A, et al. Int J Cardiol 2022; epub ahead of press.

Radcliffe Content

Electrocardiographic Findings in Patients with Severe COVID-19: Characterisation and Clinical Correlations

Journal of Asian Pacific Society of Cardiology 2024;3:e38.

Hypertrophic Cardiomyopathy as a Form of Heart Failure with Preserved Ejection Fraction: Diagnosis, Drugs, and Procedures

US Cardiology Review 2024;18:e17.

Imaging Advances in Heart Failure

Cardiac Failure Review 2024;10:e12.

Apical Hypertrophic Cardiomyopathy in Middle-aged Male with Chest Pain

US Cardiology Review 2024;18:e15.

Management of Post-cardiotomy Shock

US Cardiology Review 2024;18:e11.

Executive Summary from the 2023 Charleston HFpEF Conference

US Cardiology Review 2024;18:e07.

The Unwanted Soft Spot: A Rare Case of Biventricular Non-compaction Cardiomyopathy Causing Heart Failure in an Adult Filipino Male

Journal of Asian Pacific Society of Cardiology 2024;3:e18.

Evaluating Biomarkers as Tools for Early Detection and Prognosis of Heart Failure: A Comprehensive Review

Cardiac Failure Review 2024;10:e06.

Coronary Revascularisation in Heart Failure with Reduced Ejection Fraction

Journal of Asian Pacific Society of Cardiology 2024;3:e14

Cardiac Amyloidosis: Everywhere, but Nowhere

Journal of Asian Pacific Society of Cardiology 2024;3:e05

In Cardiogenic Shock, Age is Not Just a Number

Cardiac Failure Review 2024;10:e04.

Red Flags in Acute Myocarditis

Cardiac Failure Review 2024;10:e02.

Multisystem Inflammatory Syndrome in an Adult: A Rare Cause of ST-Segment Elevation MI

Journal of Asian Pacific Society of Cardiology 2023;2:e44.

Explaining the Unexplained: A Practical Approach to Investigating the Cardiac Arrest Survivor

Arrhythmia & Electrophysiology Review 2023;12:e27

Risk Factors for Aortic Dissection

US Cardiology Review 2023;17:e17.

Cardiovascular Involvement in Fabry’s Disease: New Advances in Diagnostic Strategies, Outcome Prediction and Management

Cardiac Failure Review 2023;9:e12.

Contemporary Review of the Management of Left Ventricular Thrombus

Journal of Asian Pacific Society of Cardiology 2023;2:e23.

How Can We Survive the Heart Failure Pandemic Era? Basic Research for Understanding the Pathophysiology of Heart Failure and Development of Novel Therapies

Journal of Asian Pacific Society of Cardiology 2023;2:e15.

Role of Imaging in Cardiomyopathies

Cardiac Failure Review 2023;9:e08.

Review Articles

Role of cardiac magnetic resonance (CMR) in planning ventricular septal myomectomy in patients with hypertrophic obstructive cardiomyopathy (HOCM)

Alenezi F, Alajmi H, Agarwal R, Zwischenberger BA. J Card Surg 2022;37:4186–9.

The uptake and utility of genetic testing and genetic counseling for hypertrophic cardiomyopathy—a systematic review and meta-analysis

Cirino AL, Harris SL, Murad AM, et al. J Genet Couns 2022;31:1290–305.

Systematic review and meta-analysis of cardiovascular consequences of myocardial bridging in hypertrophic cardiomyopathy

Bruce C, Ubhi N, McKeegan P, Sanders K. Am J Cardiol 2023;188:110–9.

Mavacamten: a novel disease-specific treatment for hypertrophic cardiomyopathy

Capilupi MJ, Frishman WH. Cardiol Rev 2023;31:45–51.

One gene, two modes of inheritance, four diseases: a systematic review of the cardiac manifestation of pathogenic variants in JPH2-encoded junctophilin-2

Parker LE, Kramer RJ, Kaplan S, Landstrom AP. Trends Cardiovasc Med 2023;33:1–10.

Comparison of demographic, clinical, biochemical, and imaging findings in hypertrophic cardiomyopathy prognosis: a network meta-analysis

Georgiopoulos G, Figliozzi S, Pateras K, et al. JACC Heart Fail 2023;11:30–41.

Mavacamten, a first-in-class cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy

Dalo JD, Weisman ND, White CM. Ann Pharmacother 2022; epub ahead of press.

Mavacamten treatment for hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials

Ismayl M, Abbasi MA, Marar R, et al. Curr Probl Cardiol 2023;48:101429.

Is there referral bias in outcomes of septal myectomy for hypertrophic cardiomyopathy?

Calderon-Rojas R, Nguyen A, Nishimura RA, et al. J Thorac Cardiovasc Surg 2022;164:881–91.

Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline

Tamargo J, Tamargo M, Caballero R. Expert Opin Investig Drugs 2022;31:1027–52.

Microvascular dysfunction in hypertrophic cardiomyopathy

Pelliccia F, Cecchi F, Olivotto I, Camici PG. J Clin Med 2022;11:6560.

The role of the submitral apparatus in hypertrophic obstructive cardiomyopathy

Tao J, Duan F, Long J, et al. J Am Soc Echocardiogr 2022; epub ahead of press.

Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis

Antonopoulos AS, Panagiotopoulos I, Kouroutzoglou A, et al. Eur J Heart Fail 2022;24:1677–96.

Athletic activity for patients with hypertrophic cardiomyopathy and other inherited cardiovascular diseases: JACC Focus Seminar 3/4

Semsarian C, Gray B, Haugaa KH, et al. J Am Coll Cardiol 2022;80:1268–83.

Implantable defibrillators in primary prevention of genetic arrhythmias. A shocking choice?

Corrado D, Link MS, Schwartz PJ. Eur Heart J 2022;43:3029–40.

Latent outflow tract obstruction in hypertrophic cardiomyopathy: clinical characteristics and outcomes of septal myectomy

Cui H, Schaff HV, Nishimura RA, et al. J Thorac Cardiovasc Surg 2022;164:1863–9.e1.